These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
925 related articles for article (PubMed ID: 30099447)
1. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo. Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447 [TBL] [Abstract][Full Text] [Related]
2. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia. Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658 [TBL] [Abstract][Full Text] [Related]
3. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway. Lin KN; Jiang YL; Zhang SG; Huang SY; Li H Biomed Pharmacother; 2020 May; 125():109885. PubMed ID: 32007917 [TBL] [Abstract][Full Text] [Related]
4. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death. Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759 [TBL] [Abstract][Full Text] [Related]
5. Rhein exerts anti-multidrug resistance in acute myeloid leukemia via targeting FTO to inhibit AKT/mTOR. Zhang S; Zhou L; Yang J; Lu J; Tao L; Feng Y; Cheng J; Zhao L Anticancer Drugs; 2024 Aug; 35(7):597-605. PubMed ID: 38728095 [TBL] [Abstract][Full Text] [Related]
6. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia. Deng L; Jiang L; Lin XH; Tseng KF; Liu Y; Zhang X; Dong RH; Lu ZG; Wang XJ Acta Pharmacol Sin; 2017 Mar; 38(3):382-391. PubMed ID: 28042875 [TBL] [Abstract][Full Text] [Related]
7. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth. Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251 [TBL] [Abstract][Full Text] [Related]
9. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249 [TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells. Bertacchini J; Frasson C; Chiarini F; D'Avella D; Accordi B; Anselmi L; Barozzi P; Forghieri F; Luppi M; Martelli AM; Basso G; Najmaldin S; Khosravi A; Rahim F; Marmiroli S Adv Biol Regul; 2018 May; 68():2-9. PubMed ID: 29576448 [TBL] [Abstract][Full Text] [Related]
11. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia. Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781 [TBL] [Abstract][Full Text] [Related]
13. Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft. Lee WJ; Hsiao M; Chang JL; Yang SF; Tseng TH; Cheng CW; Chow JM; Lin KH; Lin YW; Liu CC; Lee LM; Chien MH Arch Toxicol; 2015 Jul; 89(7):1103-17. PubMed ID: 25138434 [TBL] [Abstract][Full Text] [Related]
14. [Reversing effects of emodin on multidrug resistance in resistant HL-60/ADR cells]. Chen YY; Li J; Hu JD; Zheng J; Zheng ZH; Zhu LF; Chen XJ; Lin ZX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1413-22. PubMed ID: 24370022 [TBL] [Abstract][Full Text] [Related]
15. Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of K Lowinus T; Heidel FH; Bose T; Nimmagadda SC; Schnöder T; Cammann C; Schmitz I; Seifert U; Fischer T; Schraven B; Bommhardt U Cell Commun Signal; 2019 Jan; 17(1):5. PubMed ID: 30651113 [TBL] [Abstract][Full Text] [Related]
16. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100 [TBL] [Abstract][Full Text] [Related]
17. Molecular target therapy of AKT and NF-kB signaling pathways and multidrug resistance by specific cell penetrating inhibitor peptides in HL-60 cells. Davoudi Z; Akbarzadeh A; Rahmatiyamchi M; Movassaghpour AA; Alipour M; Nejati-Koshki K; Sadeghi Z; Dariushnejad H; Zarghami N Asian Pac J Cancer Prev; 2014; 15(10):4353-8. PubMed ID: 24935396 [TBL] [Abstract][Full Text] [Related]
18. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685 [TBL] [Abstract][Full Text] [Related]
19. Involvement of PI3K/Akt, ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis. Cui Y; Lu P; Song G; Liu Q; Zhu D; Liu X Food Chem Toxicol; 2016 Jun; 92():26-37. PubMed ID: 27032576 [TBL] [Abstract][Full Text] [Related]
20. PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis. Ryu MJ; Han J; Kim SJ; Lee MJ; Ju X; Lee YL; Son JH; Cui J; Jang Y; Chung W; Song IC; Kweon GR; Heo JY Oncol Rep; 2019 Nov; 42(5):2149-2158. PubMed ID: 31545464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]